|
CHARLES RIVER LAB, (CRL) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Charles River Laboratories International, Inc. provides research tools and integrated support services that enable the drug discovery and development process. It operates in three segments: Research Models and Services (RMS), Preclinical Services, and Clinical Services. RMS segment produces and sells research models, primarily genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist its customers in screening drug candidates. In addition, RMS offers transgenic services, laboratory services, consulting and staffing services, vaccine support, and in vitro technology services. Preclinical Services segment offers services in the areas, such as general and specialty toxicology, pathology, interventional and surgical, biopharmaceutical, pharmacokinetic and metabolic analysis, and bioanalytical chemistry. Clinical Services segment conducts Phase I clinical trials; and provides Phase II-IV clinical trials management services, which include testing, medical data sciences services, and regulatory support. Charles River Laboratories sells its products and services primarily through its direct sales force supplemented by a network of international distributors in the United States, Europe, and Japan. The companys customer base includes pharmaceutical, biotechnology, and animal health and medical device companies, as well as various government agencies, hospitals, and academic institutions. It operates approximately 100 facilities in 20 countries worldwide. Charles River Laboratories was incorporated in 1994 and is headquartered in Wilmington, Massachusetts.
|
|
